Purple Biotech Ltd. Sponsored ADR

PPBT Healthcare Biotechnology

In the quarter to June 2026, EPS grew 110.2% and free cash flow fell 62.1%, each against the same quarter a year earlier.

1.14 0.09 −7.32%
Market cap
$2.0M
P/E
0.0×
Fwd P/E
−3.7×
Dividend yield
—
F-score
2/9
Altman Z
5.49
Beneish M
−1.78
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
3.70 1.48 1.27 1.78
Net Debt/EBITDA
4.97 2.94 0.41 7.99
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(2.31) (3.35) (2.24) (2.32)
Book value per Share
11.25 10.38 20.12 72.04
Free Cash Flow
(2.51) (3.12) (1.08) (1.06)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates